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Abstract: A lifelong gluten-free diet (GFD) is the only current treatment for celiac disease (CD), but
strict compliance is complicated. Duodenal biopsies are the “gold standard” method for diagnosing
CD, but they are not generally recommended for disease monitoring. We evaluated the sensitivity
and specificity of fecal gluten immunogenic peptides (GIPs) to detect duodenal lesions in CD patients
on a GFD and compared them with serum anti-tissue transglutaminase (tTG) IgA antibodies. A
prospective study was conducted at two tertiary centers in Spain on a consecutive series of adolescents
and adults with CD who maintained a long-lasting GFD. Adherence to a GFD and health-related
quality of life were scored with validated questionnaires. Mucosal damage graded according to the
Marsh–Oberhüber classification (Marsh 1/2/3) was used as the reference standard. Of the 97 patients
included, 27 presented duodenal mucosal damage and 70 had normal biopsies (Marsh 0). The
sensitivity (33%) and specificity (81%) of GIPs were similar to those provided by the two assays used
to measure anti-tTG antibodies. Scores in questionnaires showed no association with GIP, but an
association between GIPs and patients’ self-reported gluten consumption was found (p = 0.003). GIP
displayed low sensitivity but acceptable specificity for the detection of mucosal damage in CD.
Keywords: celiac disease; gluten-free diet monitoring; Marsh–Oberhüber type; gluten immunogenic
peptides; anti-tissue transglutaminase antibodies; diagnostic accuracy
1. Introduction
Celiac disease (CD) is a chronic immune-mediated enteropathy, triggered and main-
tained by gluten consumption in genetically predisposed individuals, and characterized
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by damage of variable intensity in their duodenal mucosa [1]. A lifelong adherence to a
gluten-free diet (GFD) is currently the only therapy for these patients, which usually leads
to complete mucosal recovery. However, strict compliance to a GFD can be compromised
by unnoticed gluten consumption, cross-contamination, or social pressure when eating out
and unspecific or even absent symptomatology after transgressions [2]. As a consequence,
30% to 60% of patients with CD are exposed to gluten despite their best efforts [3–5].
Continuous gluten exposure causes permanent damage in the duodenal mucosa of
celiac patients and increases the risk of bone and endocrinological diseases [6] or intestinal
lymphoma [7]; lack of adherence to a GFD also reduces health-related quality of life
(HRQoL) [8]. Monitoring sustained adherence to a GFD in celiac patients is, therefore,
essential. This is mainly undertaken by surveying symptoms, administering nutritional
questionnaires, and using non-invasive serological markers. The assessment of duodenal
biopsies, which is considered the gold standard, is rarely performed during the follow-up
of CD due to its invasiveness, relative risk, and high cost [9]. Persistence of duodenal
mucosal lesions is more commonly found in adults compared to children and in those with
a shorter time on a GFD [10,11].
There is a general consensus about the limitations of both patient-reported question-
naires and serological tests in detecting gluten transgressions and persistence of mucosal
damage during the follow-up of CD [12,13]. Anti-tissue transglutaminase (tTG) and
anti-endomysium antibodies are highly sensitive markers for the diagnosis of CD, but a
meta-analysis showed their sensitivity in identifying villous atrophy fell below 50% once
patients were on a GFD [14]. Therefore, celiac patients with negative antibody levels during
follow-up could have undetected duodenal damage for years.
The detection in urine and fecal samples of gluten immunogenic peptides (GIPs),
responsible for most of the immune-toxic reactions mediated by gluten in CD patients [15],
has been proposed as being useful to check GFD compliance [16]. A manufacturer-
sponsored study showed that 71% of the patients with Marsh type 2/3 lesions in duodenal
biopsies showed negative serum antibodies, while positive urine GIPs were detected in all
of the patients [17]. GIP measurement in stools, where they are present for 2–4 days after
gluten ingestion, has been used to monitor adherence to GFD [18–20]. However, to date,
no independent studies have evaluated the correlation between GIP detection in feces and
changes in the duodenal mucosal histology in a real-life clinical setting.
In this study, our aim was to ascertain the utility of measuring GIPs with a qualitative
lateral-flow immunochromatography assay in a single stool sample to detect duodenal
mucosal lesions. To that end, we recruited adolescent and adult patients with CD in a
clinical setting in two Spanish tertiary hospitals and assessed whether performing fecal GIP
during CD monitoring is superior to serum tTG IgA antibodies’ measurement, as an index
test, in detecting mucosal lesions by comparing them to the clinical reference standard:
histopathological analysis of duodenal biopsies. In addition, HRQoL and patient-declared
adherence to a GFD were measured to check for relationships between histological and
laboratory results.
2. Subjects and Methods
2.1. Study Design and Reporting
The protocol was designed as a prospective observational study to evaluate the
diagnostic accuracy of laboratory tests. The whole manuscript has been redacted to fulfill
the essential items for the Standards for Reporting of Diagnostic Accuracy Studies, STARD
2015 [21].
2.2. Study Population
A consecutive series of adolescents and adult patients (age ≥ 14 years) with an
established diagnosis of CD, more than one year on a GFD, and who attended either the
Gastroenterology out-patient clinic at Hospital General de Tomelloso (HGT, Tomelloso,
Spain) or Hospital Universitario de La Princesa (HUP, Madrid, Spain) between May 2018
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and July 2020 were invited to participate in this study. Pregnant women, patients with other
concomitant severe diseases, those with wheat allergy, non-celiac gluten sensitivity, and
known refractory CD were not invited to participate. No prior calculation of sample size
was performed. Recruited patients were given an appointment for an upper endoscopy and
instructed to collect a fecal sample the day before the appointment. They were instructed
to keep the sample at 4 ◦C until it was brought to the hospital.
2.3. Upper Endoscopy and Duodenal Biopsies
An esophago-gastro-duodenoscopy (EGD) under sedation with propofol was per-
formed according to clinical practice. As per protocol, five biopsies from the second portion
of the duodenum and two more from the duodenal bulb were obtained from each patient
to investigate the persistence of mucosal lesions [22]. No reported adverse event occurred
in any of the patients during the EGD.
The paraffin-embedded samples were cut, stained with hematoxylin–eosin, and stud-
ied under a light microscope by a single expert pathologist, blind to clinical and laboratory
data, at each institution. Only representative and carefully orientated mucosal sections
were included in the histopathological analysis. Quantification of the intraepithelial lym-
phocytes was performed through immunohistochemical examinations and using CD3
monoclonal antibodies for doubtful cases (Roche Diagnostics, Penzberg, Germany). The
mucosal specimens were graded independently in accordance with the Marsh–Oberhüber
classification: infiltration of intraepithelial lymphocytes >25% (type 1), crypt hyperplasia
(type 2), and villous atrophy (type 3) [23,24]. This classification is widely accepted as a
reference standard for CD assessment in clinical practice [22]. Presence of mucosal damage
was considered when Marsh types 1, 2 or 3 were reported by the pathologists.
2.4. Measurement of GIPs
Patient stool samples were frozen at −40 ◦C as soon as they were delivered to medical
staff, before the EGD. For GIP measurement, the samples were defrosted for 4–5 h and later
homogenized. GIP detection was performed for all samples at HGT using iVYCHECK
GIP-Stool (Biomedal, Sevilla, Spain) and following the manufacturer instructions. This
assay is based on lateral-flow immunochromatography and provides a qualitative result.
Interpretation was visually performed after 30 min of sample pouring. The presence of both
green and red lines was considered GIP positive while the presence of only a green band
was interpreted as GIP negative. Samples with the appearance of a green line at 30 min
but not at 10 min were considered weak positives. No indeterminate results (presence of
red band in absence of green band) were obtained. The limit of detection of the test was
0.15 µg GIP/g of stool, so this cutoff point represents the GIP concentration above which
the test was positive.
GIP tests were performed in batches of several samples (normally 4 to 6) without
knowing the reference standard results.
2.5. Measurement of Anti-tTG IgA
Blood from patients was extracted just before EGD for serum anti-tTG IgA determina-
tion. In addition, serum IgA levels were also measured to detect IgA deficiency, which was
confirmed when the IgA concentration was lower than 70 mg/dL.
In HGT, anti-tTG IgA was measured with Liaison tTG IgA assay (DiaSorin, Salug-
gia, Italy) and manufacturer reference values were 0–8 UA/mL (lower limit of detection
0.2 UA/mL). Therefore, the test was interpreted as positive for anti-tTG concentrations
above 8 UA/mL in the absence of IgA deficiency.
In HUP, anti-tTG IgA was measured with Quanta Flash IgA tTG assay (Werfen Diag-
nostics, Barcelona, Spain) and manufacturer reference values were 0–20 UA/mL (lower
limit of detection 1.9 UA/mL). Consequently, the test was interpreted as positive for
anti-tTG concentrations above 20 UA/mL in the absence of IgA deficiency.
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At both sites, blood samples were processed in the corresponding auto-analyzers
the day after the EGD, so the anti-tTG IgA result was completed for each patient before
reference standard results were available. No indeterminate results were obtained from
any sample, and patients with IgA deficiency were excluded from the final analyses.
2.6. Gluten-Free-Diet Adherence and HRQoL Questionnaires
On the same day and just prior to the EGD exam, patients were asked to complete two
questionnaires previously adapted and validated linguistically and culturally in Spanish.
HRQoL was assessed using a celiac-specific questionnaire. This is a self-administered
questionnaire, with 20 items across four clinically relevant subscales and answered using a
Likert scale. The overall score is expressed on a scale of 20 to 100 points, with higher scores
indicating better health and lower ones indicating higher stress levels due to CD [25].
The Spanish translation of the Celiac Dietary Adherence Test (CDAT) was used to
evaluate adherence to the GFD; this consists of 7 items with a five-point scale for each item
(7 to 35 points). Higher scores reflect poor adherence to GFD; with the last item asking
about self-conscious gluten ingestion [26].
2.7. Statistical Analyses
Mean and standard deviations were reported for continuous variables and propor-
tions for categorical data. The normality of continuous variables was checked using
the Kolmogorov–Smirnov test. The Student t-test was employed for normal-distributed
variables, while the U-Mann–Whitney test was used when normality was absent. For
categorical data, contingency tables were produced and analyzed by chi-square or Fisher
exact tests.
Sensitivity, specificity, positive predictive value (PPV), negative predictive value
(NPV), and their 95% confidence intervals (95% CI) were calculated for GIP and tTG
performance compared to the gold standard, which was the presence of any mucosal
damage in the duodenum according to Marsh–Oberhüber classification. The percentage
of agreement between methods was also calculated. The Kappa statistic was used for
concordance between GIPs and mucosal lesions, as both were interpreted qualitatively. In
addition, quantitative tTG values were employed to calculate the area under the receiver
operating characteristic curve (AUC-ROC) and to estimate the optimal cutoff value by
using the Youden index.
All statistical analyses were carried out using PASW version 18.0 (SPSS Inc., Chicago,
IL, USA), GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, USA), and Epi-
dat v4.2 (Servicio Gallego de Salud, Santiago de Compostela, Spain). Statistical significance
was considered when p < 0.05.
3. Results
3.1. Demographic and Clinical Characteristics of Patients
Ninety-eight patients underwent EGD and provided fecal and serum samples (Figure 1).
One patient from HGT was excluded due to a problem with biopsy sample processing
at the Pathology Department. Table 1 shows the characteristics of the 97 patients finally
included in the study. A female:male ratio of 3:1 was found, in agreement with the reported
CD sex distribution. Mean age was close to 40 years old, and patients were on a GFD for a
mean of 105 months, that is, almost 9 years. Most patients (62%) presented villous atrophy
(Marsh 3) at the point of diagnosis.
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Table 1. Demographic and clinical characteristics of patients included in the study and statistical comparison between both
recruiting hospitals.
Total HGT HUP p
Patients 97 64 33
Sex
Female 75 (77.3%) 48 (75.0%) 27 (81.8%)
0.477
Male 22 (22.7%) 16 (25.0%) 6 (18.2%)
Age (years) 39.7 ± 18.0 (14–77) 38.0 ± 19.2 (14–75) 43.2 ± 15.1 (20–77) 0.180
Age (years) at diagnosis 31.0 ± 19.9 (0–72) 29.1 ± 21.1 (1–68) 34.6 ± 17.1 (0–72) 0.168
Months in GFD 104.9 ± 89.7 (12–362) 106.3 ± 84.4 (12–362) 102.1 ± 100.6 (12–318) 0.826
Marsh type at diagnosis (%)
Marsh 3 60 (61.9%) 38 (59.4%) 22 (66.7%)
0.313
Marsh 2 9 (9.3%) 8 (12.5%) 1 (3.0%)
Marsh 1 11 (11.3%) 7 (10.9%) 4 (12.1%)
Unknown 17 (17.5%) 11 (17.2%) 6 (18.2%)
Marsh type currently (%) a
Marsh 3 3 (3.1%) 0 3 (9.1%)
0.695
Marsh 2 3 (3.1%) 3 (4.7%) 0
Marsh 1 21 (21.6%) 14 (21.9%) 7 (21.2%)
Marsh 0 70 (72.2%) 47 (73.4%) 23 (69.7%)
Positive fecal GIPs (%) b 22 (22.7%) [54.5%] 15 (23.4%) [53.3%] 7 (21.2%) [57.1%] 0.804
Positive serum anti-tTG IgA (%) c 11 (11.8%) 2 (3.3%) 9 (28.1%) 0.001
Health-related quality of life score d 71.6 ± 12.1 (39–96) 71.0 ± 12.7 (39–96) 72.7 ± 10.9 (40–89) 0.520
CDAT score e 12.2 ± 4.0 (7–27) 12.2 ± 3.9 (7–24) 12.1 ± 4.3 (7–27) 0.910
Self-reported gluten consumption (%) f 17 (17.5%) 15 (23.4%) 2 (6.1%) 0.033
HGT: Hospital General de Tomelloso; HUP: Hospital Universitario de La Princesa; GFD: gluten-free diet; GIPs: gluten immunogenic
peptides; tTG IgA: tissue transglutaminase immunoglobulin A; CDAT: Celiac Dietary Adherence Test. Significant differences between
patients recruited in different hospitals are highlighted in bold. a Marsh 2 and Marsh 3 were grouped together for the statistical comparison
between hospitals. b The percentage of total positives considered as weak positives (GIP band visible at 30 min but not at 10 min) is showed
in brackets. c Three patients from HGT and one patient from HUP are not included as they presented IgA deficiency. d Higher scores
indicate better quality of life. e Higher scores indicate worse adherence to a GFD. f Patient self-reported gluten consumption in the last
month based on the response to the last question of adherence to GFD questionnaire.
Characteristics of patients recruited at the two hospitals were similar (Table 1), with
no differences detected for most variables. However, serum anti-tTG was most frequently
positive at HUP (p = 0.001), and more patients at HGT declared self-reported gluten
consumption in the last month (p = 0.033).
No differences were observed in the age of the patients with complete mucosal recov-
ery (Marsh type 0) compared to those with Marsh 1/2/3 (mean and SD being 38.9 ± 18.0
vs. 41.9 ± 18.1 years; p = 0.466). However, complete mucosal recovery was associated with
longer duration of the GFD rather than presence of any mucosal damage (114.9 ± 96.7 vs.
78.9 ± 62.9 months; p = 0.035).
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GIPs were detected in 22.7% of the patients, ith no differences bet een recruiting
hospitals a i than half of the samples (55%) being weak positives. No differences
i sex, ag , length on a GFD, and M rsh type at diagnosis were obs rved b tw en pati nts
with positive and neg tive GIP results.
Compared to duodenal histology as the gold standard, the sensitivity and specificity
of IPs any mucosal damage wer 33. % (CI 95%, 18.6–52.2%) and 81.4% (CI 95%,
70.8–88.8%), respectively (Table 2). PPV and NPV were 40.9% (CI 95%, 23.3–61.3%) and
76% (CI 95%, 65.2–84.2%), respectively, with an agreem nt of 68% and kappa of 0.157
(CI 95%, −0.053 to 0.366) GIPs were undetected in 4 of the 6 patients with the most severe
mucosal damage (Marsh type 2/3) (Table 3).
Table 2. Diagnostic performance of presence of gluten immunogenic peptides (GIPs) in stool and serum anti-tissue
transglutaminase (tTG) IgA assays to detect mucosal damage in duodenal biopsies.
Marsh0 Marsh1/2/3 Total AUC AG SE SP PPV NPV
GIP (iVYCHECK, Biomedal)
Positive (>0.15 µg/g) 13 9 22 - 68.0% 33.3% 81.4% 40.9% 76.0%
Negative (<0.15 µg/g) 57 18 75
Anti-tTG IgA (Liaison, Diasorin)
Positive (>8 UA/mL) 0 2 2
0.549 75.4 11.8% 100% 100% 74.6%
Negative (<8 UA/mL) 44 15 59
Anti-tTG IgA (Quanta Flash, Werfen)
Positive (>20 UA/mL) 3 9
0.564 59.4% 30.0% 72.7% 33.3% 69.6%
Negative (<20 UA/mL) 16 7 23
AUC: area under the receiver operating characteristic curve; AG: agreement; SE: sensitivity; SP: specificity; PPV: positive predictive value;
NPV: negative predictive value.
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Table 3. Demographic data, clinical characteristics, and laboratory results for patients with Marsh type 2/3 in the duodenal
biopsy.



















Neg 2.0 305 80 17
Yes16 38 Pos
1.6 205 64 11
Male 19 77 14.2 329 58 17




169.9 258 62 19
No39 56 4.1 212 86 9
26 302 Unknown <1.9 172 85 14
HGT: Hospital General Tomelloso; HUP: Hospital Universitario de La Princesa; y: years; dx: when celiac disease was diagnosed. GFD:
gluten-free diet; m: months; GIPs: gluten immunogenic peptides in stool; Neg: negative; Pos: positive; tTG IgA: tissue transglutaminase
immunoglobulin A; HRQoL: health-related quality of life; CDAT: Celiac Dietary Adherence Test. Gluten intake was based on self-reported
gluten consumption in the last question of the adherence to gluten-free diet questionnaire.
3.3. Performance of Serum Anti-tTG IgA Antibodies to Detect Mucosal Damage
Anti-tTG IgA assays were different in the two recruiting hospitals, resulting in different
concentrations and positivity rates. Therefore, both assays were analyzed separately.
Liaison anti-tTG assay showed no significant association with Marsh type (p = 0.074),
and the sensitivity and specificity to detect any mucosal lesion were 11.8% (CI 95%,
3.3–34.3%) and 100% (CI 95%, 92–100%), respectively (Table 2). The only two patients
with tTG concentration above the cutoff value (8 UA/mL) presented mucosal lesions, thus
resulting in high specificity. The agreement was 75.4%, with a PPV and NPV of 100%
(CI 95%, 34.2–100%) and 74.6% (CI 95%, 62.2–83.9%), respectively. The AUC-ROC was
0.549 (CI 95%, 0.380–0.718) (Supplementary Materials Figure S1), with an optimized cutoff
concentration of 0.85 UA/mL, which, however, displayed limited sensitivity (64.7%) and
specificity (50%).
Likewise, poor sensitivity (30%, CI 95%, 6.7–65.3%), moderate specificity (72.7%,
CI 95%, 49.8–89.3%), and no association with Marsh type (p = 1.0) was observed for the
Quanta Flash anti-tTG assay (Table 2). Only one out of three patients with Marsh 3 biopsies
displayed tTG levels above the cutoff (20 UA/mL) (Table 3). The agreement was lower
than for the Liaison assay (59.4%), providing also a lower PPV (33.3%, CI 95%, 13.5–61.6%)
and NPV (69.6%, CI 95%, 58.6–78.7%). The AUC-ROC was similar to that calculated for
the Liaison anti-tTG assay (0.564, CI 95%, 0.348–0.780) (Supplementary Materials Figure
S1), with equally limited performance of the optimized cut-off concentration (4.0 UA/mL,
sensitivity = 80% and specificity = 40.9%).
3.4. Association between Serum Antibodies and GIP Results
No differences were detected for quantitative anti-tTG serum values between GIP-
positive and GIP-negative patients for any of the anti-tTG assays (p = 0.884 for Liaison
assay and p = 0.755 for Quanta Flash assay) (Supplementary Materials Figure S2).
If serum anti-tTG results were interpreted as positive or negative according to the
manufacturers’ recommended cutoff, a close-to-significance association was found between
Liaison anti-tTG assay and stool GIPs (p = 0.050), as GIPs were detected in the two patients
with positive tTG. Conversely, no relationship was observed between Quanta Flash anti-
tTG assay and GIP detection (p = 1.0).
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3.5. Patients’ Scores from Questionnaires and Relationship with Demographics, Mucosal Damage,
and Laboratory Markers
HRQoL and adherence to GFD (CDAT score) inversely correlated (Pearson’s
r = −0.099 ± 0.032; p = 0.003) in the sense that a poorer QoL level was associated with a
lower adherence to GFD (Supplementary Materials Figure S3).
However, no significant association was observed between HRQoL and CDAT scores
when groups were compared for the following variables: age group (14–25 years,
26–55 years, >55 years), sex, length on a GFD (12–36 months, 37–120 months, >120 months),
presence of mucosal damage (Marsh 0 vs. Marsh 1/2/3), and GIP detection. The only
association found was patients with positive anti-tTG recruited at HUP showing worse
adherence to a GFD (higher CDAT scores) than those with negative ones (14.6 ± 5.8 vs.
11.1 ± 3.2; p = 0.038).
An association between patient self-reported gluten consumption in the previous
month (last question of CDAT questionnaire) and GIP detection was found (p = 0.003).
GIPs were more frequently detected in patients who were aware of any gluten consumption
in the last month (52.9%) than in those who believed that they had not ingested gluten at
all (16.3%) (Table 4). This also showed that almost 60% of patients with positive GIPs were
not aware of gluten transgressions.
Table 4. Relationship between detection of gluten immunogenic peptides (GIPs) in stool and patient
self-reported gluten consumption in the last month before gastroscopy was performed.
GIP Negative GIP Positive Total
Gluten consumption 8 (47.1%) 9 (52.9%) 17
No gluten consumption 67 (83.7%) 13 (16.3%) 80
75 22 97
4. Discussion
Patients with CD should be monitored to ensure the achievement of positive health
outcomes and an appropriate reversion of the mucosal damage caused by gluten. However,
monitoring strict compliance of a GFD is controversial in CD management [27]. Although
there are several options to evaluate this compliance (presence of symptoms, HRQoL
questionnaires, self-reported adherence to a GFD, nutritional counseling, dietary reports,
serological assays, and endoscopy with duodenal biopsies), there is no consensus on a
suitable methodology and frequency of follow-up in practice guidelines [9,28]. In our study,
we have assessed the diagnostic accuracy of stool GIPs measured with a qualitative assay
to detect mucosal damage in CD patients on a long-term GFD by comparing GIP results
with the reference standard method. To our knowledge, this is the first study without GIP
manufacturer funding addressing the capability of stool GIPs to detect mucosal damage
during monitoring of CD patients in a real-life clinical setting. According to our results,
GIPs had similar sensitivity and specificity to serum anti-tTG IgA for detecting any mucosal
damage (Marsh type 1/2/3), with 22.7% of patients having gluten transgressions according
to single stool GIP detection.
Persistence of mucosal damage is associated with non-responsive CD, which is mostly
caused by gluten exposure and rarely (1–3% of patients) by refractory CD [29]. However,
current consensus does not recommend endoscopy for routine monitoring of CD, only
for complicated cases with persisting symptoms and laboratory-proved deficiencies in
micronutrients [9]. Therefore, it is not rare that asymptomatic patients with negative
serology have no second endoscopy after CD diagnosis for years, thus missing possible
mucosal lesions [13]. Although recognized as the reference standard method, the specific
role of endoscopic surveillance in CD follow-up still needs to be defined [27,30].
Severe mucosal damage (Marsh type 2/3) was found in 6.2% of our cohort, less
than expected according to some previous publications [3–5,31], but in agreement with
other studies reporting ratios of 4–6% after a long-term GFD [32,33]. Patients with mild
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mucosal damage (Marsh 1 or intraepithelial lymphocytosis) represented 21.6% of our
cohort. We assumed that this was caused by persistent CD activity, although mild mucosal
damage could be present in other conditions, such as Helicobacter pylori infection, parasitic
infections (mainly, Giardia lamblia), small intestinal bacterial overgrowth, lymphocytic
colitis, food allergies, or non-steroidal anti-inflammatory treatment [1]. Marsh 1 lesions are
present in some CD patients who strictly adhere to a GFD [32] and even persist after GFD
optimization [34], so the clinical significance and long-term impact of prolonged duodenal
intraepithelial lymphocytosis needs to be investigated further.
As expected, serum anti-tTG IgA assays from different manufacturers varied in nu-
merical values and positivity rates [35]. Despite serum anti-tTG usually falling below the
positive threshold one-year after setting up a GFD [36], serology shows low sensitivity for
detecting mucosal damage beyond CD diagnosis [14]. Therefore, negative serology does
not necessarily indicate mucosal healing. Some alternatives were proposed to improve
anti-tTG performance, including the use of undetectable levels as a marker of damage
absence [31], employment of reference change values [37], or defining “compliance” in
addition to “diagnostic” cutoffs [38]. Regarding the latter, optimized cutoff points ac-
cording to the Youden index still showed poor diagnostic accuracy in the anti-tTG assays
tested, with increases in sensitivity balanced by great decreases in specificity. In our study,
the main advantage of Liaison anti-tTG assay was the absence of false positives, as the
two patients with positive concentrations had mucosal damage, while positive results
in Quanta Flash assay were associated with lower adherence to a GFD measured by the
CDAT questionnaire. In contrast, no association was observed between serum anti-tTG
IgA concentrations and GIP results as also reported in previous studies [20,39], although
others did find agreement between the two tests [40].
A single GIP determination displayed positive results in 22 patients (22.7%) and was
associated with self-reported gluten consumption. Initial studies assessing urine or stool
GIPs provided higher rates of 29.8% [16] and 46.5% [17], with positivity increasing further
to between 58% to 89% when several samples were taken from the same patient over
a period [20,39]. In these latest two studies, an increased span of testing, however, led
to detecting patients with positive GIPs but no duodenal damage. In our cohort, GIPs
were also detected in 13 patients (13.4%) with no mucosal damage (Marsh type 0), with
5 of them reporting gluten consumption the month before EGD. A potential tolerance of
small amounts of gluten [41] or delay in appearance of mucosal damage could explain this
finding, which deserves further investigation. Anyway, although frequency and number
of determinations for stool GIP testing have not been established for clinical routine, our
results and others from previous publications indicate that the more tests performed, the
more patients without mucosal damage will have positive GIPs, which could result in
unnecessary increases in costs of CD follow-up.
It should be noted that stool GIPs reflect gluten consumption 2–4 days before the
sample is provided, so its use as a surrogate marker for mucosal damage, as suggested in
some manufacturer-funded studies, needs to be evaluated carefully. Manufacturer-funded
research assessing this issue showed good agreement (80–100%) between persistence of
villous atrophy (Marsh types 2/3) and detectable GIPs in either urine [17,39] or both stool
and urine [19]. However, our study found negative GIPs in 4 out of 6 patients with Marsh
type 2/3 using a single determination in stool, overall providing remarkably low sensitivity
(33.3%) and PPV (40.9%). Therefore, it would be advisable to combine GIP with other tools.
A recent study suggested combining fecal GIPs with a CDAT questionnaire as the best
option for monitoring dietary compliance in celiac patients [42].
Among the limitations of our study, the low number of patients with villous atrophy
prevented us from specific analyses for this group of patients. The long period of our
cohort on a GFD was the likely cause of this, as reported in other cohorts with long lasting
adherence. Marsh type 1 was interpreted as being caused by CD, but other potential
causes of intraepithelial lymphocytosis should also be acknowledged. Knowing that the
effectiveness of the diet was going to be evaluated could have led to better adherence by
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our patients, which is an intrinsic problem of GIP testing. Finally, patients with refractory
CD were not included, nevertheless the potential impact of this rare condition on our
results would be negligible given its extremely low prevalence.
5. Conclusions
To conclude, stool GIP testing could be useful in certain CD patients to identify gluten
transgression leading to persistent mucosal damage, but its sensitivity and specificity
in detecting histopathological lesions for a single measurement was not superior to that
observed for serum anti-tTG IgA. Finding non-invasive surrogate biomarkers of persistent
mucosal damage in CD is still a requirement, and the employment of different tools for CD
monitoring, depending on the particular clinical situation of each patient, would be the
most advisable approach.
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